

Agios, Celgene terminate partnership for developing cancer treatment

06 September 2018 | News

Celgene will be eligible to receive low single-digit royalties on global net sales and both companies will split certain global development costs until year-end.



Singapore - Agios Pharmaceuticals and Celgene have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881.

Global rights will revert back to Agios. Celgene will be eligible to receive low single-digit royalties on global net sales and both companies will split certain global development costs until year-end.

For a specific time period (undisclosed), Celgene and its affiliates will be prohibited from developing, manufacturing or commercializing any product containing isocitrate dehydrogenase 1 (IDH1) at specific levels of binding for any indication. Agios will be prohibited from developing, manufacturing or commercializing AG-881 in blood cancers.

The termination comes three months after Agios presented its first data from an ongoing Phase I study (NCT02481154) assessing AG-881 as a single agent in advanced glioma and other solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.